Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18364935 | 1.00 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL15151056 | 1.00 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL8498418 | 1.00 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL9527531 | 1.00 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL2913896 | 1.00 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL6906651 | 1.00 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL8854257 | 1.00 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL10005703 | 0.98 | KMT2A (0.52) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL14233382 | 0.98 | KMT2A (0.51) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL820099 | 0.98 | KMT2A (0.51) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4367087-A1 | SEPARATION PROCESS FOR THE PRODUCTION OF C5 OR C6 ALKANEDIOL | Johnson Matthey Davy Technologies Limited (GB) | 2024-05-15 | — | — | EP | claimed |
| CN-117440941-A | For the production of C 5 Or C 6 Process for the separation of alkanediol | 庄信万丰戴维科技有限公司 | 2024-01-23 | — | — | CN | claimed |
| WO-2023281247-A1 | SEPARATION PROCESS FOR THE PRODUCTION OF C5 OR C6 ALKANEDIOL | JOHNSON MATTHEY DAVY TECHNOLOGIES LIMITED (GB) | 2023-01-12 | — | — | WO | claimed |
| EP-4003314-B1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4367087-A1 | SEPARATION PROCESS FOR THE PRODUCTION OF C5 OR C6 ALKANEDIOL | Johnson Matthey Davy Technologies Limited (GB) | 2024-05-15 | — | — | EP | disclosed |
| CN-117440941-A | For the production of C 5 Or C 6 Process for the separation of alkanediol | 庄信万丰戴维科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-3694830-B1 | PRODUCTION OF 1,5-PENTANEDIOL VIA UPGRADING OF TETRAHYDROFURFURYL ALCOHOL | WISCONSIN ALUMNI RES FOUND (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230007838-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| WO-2023281247-A1 | SEPARATION PROCESS FOR THE PRODUCTION OF C5 OR C6 ALKANEDIOL | JOHNSON MATTHEY DAVY TECHNOLOGIES LIMITED (GB) | 2023-01-12 | — | — | WO | disclosed |
| US-20220402851-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-5571689-A | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid | WASHINGTON UNIVERSITY (US) | 1996-11-05 | — | — | US | disclosed |
| EP-0382213-B1 | Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent | OTSUKA PHARMA CO LTD (JP) | 1995-05-10 | — | — | EP | disclosed |
| EP-0600092-A1 | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-08 | — | — | EP | disclosed |
| EP-0441765-B1 | Novel fatty acid analog enzyme substrates | UNIV WASHINGTON (US) | 1994-05-11 | — | — | EP | disclosed |
| US-5093370-A | Useful prior to insertion of tracheotomy tube or discission | TOBISHI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1992-03-03 | — | — | US | disclosed |
| US-5082967-A | Myristolyation | WASHINGTON UNIVERSITY (US) | 1992-01-21 | — | — | US | disclosed |
| US-5053548-A | Containing hydroxy substituents; nervous system disorders | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| EP-0441765-A1 | Novel fatty acid analog enzyme substrates | WASHINGTON UNIVERSITY (US) | 1991-08-14 | — | — | EP | disclosed |
| EP-0382213-A2 | Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230007838-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | KMT2A 2198/4885MEN1 4199/4885KDM4C 2482/4885 |
| US-20220402851-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | KMT2A 2198/4885MEN1 4199/4885KDM4C 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.